DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MANNITOL 5% IN PLASTIC CONTAINER

« Back to Dashboard

All Clinical Trials for Mannitol 5% In Plastic Container

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003062	Temozolomide in Patients With Progressive or Recurrent Non-small Cell Lung Cancer	Completed	European Organisation for Research and Treatment of Cancer - EORTC	Phase 2	1997-07-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effect of temozolomide in patients with progressive or recurrent stage IV non-small cell lung cancer, with or without brain metastases, who have not been treated for metastatic disease with chemotherapy.
NCT00004767	Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders	Completed	Johns Hopkins University	Phase 2	1985-01-01	OBJECTIVES: I. Assess the safety and efficacy of sodium phenylbutyrate, sodium benzoate, sodium phenylacetate, and dietary intervention in patients with urea cycle disorders.
NCT00004767	Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders	Completed	National Center for Research Resources (NCRR)	Phase 2	1985-01-01	OBJECTIVES: I. Assess the safety and efficacy of sodium phenylbutyrate, sodium benzoate, sodium phenylacetate, and dietary intervention in patients with urea cycle disorders.
NCT00111956	Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	N/A	2004-04-01	Metabolic syndrome is associated with increased inflammatory cytokines and reduced adiponectin, that may be mediated in part by TNF production from abdominal fat. We reasoned that an anti-TNF agent would reduce C-reactive protein (CRP) and increase adiponectin, improving the inflammatory milieu associated with metabolic syndrome.

Clinical Trial Conditions for Mannitol 5% In Plastic Container

Condition Name

Condition Name for Mannitol 5% In Plastic Container
Intervention	Trials
Asthma	20
Cystic Fibrosis	9
Healthy	6
Traumatic Brain Injury	6

Condition MeSH

Condition MeSH for Mannitol 5% In Plastic Container
Intervention	Trials
Asthma	18
Intracranial Hypertension	12
Brain Injuries	9
Fibrosis	9

Clinical Trial Locations for Mannitol 5% In Plastic Container

Trials by Country

Trials by Country for Mannitol 5% In Plastic Container
Location	Trials
United States	141
United Kingdom	39
Canada	32
Australia	30
Argentina	18

Trials by US State

Trials by US State for Mannitol 5% In Plastic Container
Location	Trials
New York	18
Massachusetts	10
Ohio	8
Minnesota	8
Oregon	8

Clinical Trial Progress for Mannitol 5% In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Mannitol 5% In Plastic Container
Clinical Trial Phase	Trials
Phase 4	37
Phase 3	30
Phase 2/Phase 3	8

Clinical Trial Status

Clinical Trial Status for Mannitol 5% In Plastic Container
Clinical Trial Phase	Trials
Completed	83
Recruiting	38
Not yet recruiting	25

Clinical Trial Sponsors for Mannitol 5% In Plastic Container

Sponsor Name

Sponsor Name for Mannitol 5% In Plastic Container
Sponsor	Trials
Pharmaxis	19
Northwell Health	6
OHSU Knight Cancer Institute	6

Sponsor Type

Sponsor Type for Mannitol 5% In Plastic Container
Sponsor	Trials
Other	251
Industry	51
NIH	16